Bio-Rad Laboratories (FRA:BUWA) EBIT: €231 Mil (TTM As of Mar. 2026)


FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
72 GF Score
Price €246.00
GF Value €272.84
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories EBIT?

Bio-Rad Laboratories FRA:BUWA +3.27% 72 EBIT is €231 Mil as of Mar. 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 72/100 and a GF Value™ of €272.84 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Bio-Rad Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-586 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €231 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bio-Rad Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 1.26%. Bio-Rad Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -171.41%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bio-Rad Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.55%.


Bio-Rad Laboratories  (FRA:BUWA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bio-Rad Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=117.984 * ( 1 - 23.59% )/( (7428.006 + 6832.549)/ 2 )
=90.1515744/7130.2775
=1.26 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9032.331 - 288.567 - ( 1315.758 - max(0, 441.518 - 2481.895+1315.758))
=7428.006

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8468.35 - 282.336 - ( 1353.465 - max(0, 793.205 - 2544.916+1353.465))
=6832.549

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bio-Rad Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2344.148/( ( (606.255 + max(756.559, 0)) + (596.331 + max(775.991, 0)) )/ 2 )
=-2344.148/( ( 1362.814 + 1372.322 )/ 2 )
=-2344.148/1367.568
=-171.41 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(393.352 + 632.558 + 140.227) - (288.567 + 0 + 121.011)
=756.559

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(368.663 + 666.482 + 156.306) - (282.336 + 0 + 133.124)
=775.991

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bio-Rad Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=230.877/6495.664
=3.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Rad Laboratories EBIT Related Terms


Bio-Rad Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories EBIT Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,823.79 -4,404.80 -734.24 -2,190.39 892.00

Bio-Rad Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.25 369.86 -356.82 803.87 -586.04

FRA:BUWA vs BRKR, MASI, PODD: EBIT Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's EV-to-EBIT falls into.


FRA:BUWA
72GF Score
Bio-Rad Laboratories Inc FRA:BUWA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €231 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €231 Mil mean?
Bio-Rad Laboratories (FRA:BUWA) has a EBIT of €231 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bio-Rad Laboratories.
Is Bio-Rad Laboratories' EBIT too high?
Bio-Rad Laboratories' current EBIT is €231 Mil. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' EBIT compare to BRKR and MASI?
Bio-Rad Laboratories' EBIT of €231 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bio-Rad Laboratories. Bio-Rad Laboratories's current EBIT is €231 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Undervalued. The stock's GF Value™ is €272.84, compared to a current price of €246.00 — trading 9.8% below its estimated fair value. The current EBIT is €231 Mil. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current EBIT is €231 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €246.00 is trading 9.8% below its estimated GF Value™ of €272.84. GuruFocus considers Bio-Rad Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:BUWA:

  • EBIT: €231 Mil
  • GF Value™: €272.84 vs. price of €246.00 (9.8% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score

Get the complete analysis for FRA:BUWA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€246.00
Price
€272.84
GF Value